Lipid-lowering effect of the new drugs eniclobrate and beclobrate in patients with hyperlipidemia type II a and type II b.

Abstract

First clinical results are presented for two newly developed drugs. Both are diphenylmethane derivatives named ethyl-(+/-)-2-([alpha-(p-chlorophenyl)-p-tolyl]-oxy)-2-methylbutyrate (beclobrate, B) and (+/-)-2-(4-[(4-chlorophenyl)methyl]phenoxy)-2-methyl-butanacid-3-pyridinylmethylester (eniclobrate, E). These drugs were given in a doubleblind crossover trial with placebo periods before, in between and afterwards to 6 patients with type IIb and 13 patients with type IIa hyperlipidemia. Beclobrate was given in a dosage of 100 mg twice daily and eniclobrate in a dosage of 130 mg twice daily. Besides effectively reducing LDL-cholesterol in type IIa there was a remarkable increase in HDL-cholesterol in both types of hyperlipidemia especially for beclobrate.

• Authors: C Najemnik, H Lageder, H Regal, K Irsigler
• Journal: Arzneimittel-Forschung (Arzneimittelforschung) Vol. 31 Issue 12 Pg. 2168-9 ( 1981) ISSN: 0004-4172 [Print] Germany
• PMID: 7037012 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Benzhydryl Compounds
• Hypolipidemic Agents
• Triglycerides
• Cholesterol
• eniclobrate
• beclobrate

Topics

• Benzhydryl Compounds (therapeutic use)
• Cholesterol (blood)
• Clinical Trials as Topic
• Double-Blind Method
• Humans
• Hyperlipidemias (drug therapy)
• Hypolipidemic Agents
• Triglycerides (blood)